OA13047A - Cannabinoid receptor ligands and uses thereof. - Google Patents
Cannabinoid receptor ligands and uses thereof. Download PDFInfo
- Publication number
- OA13047A OA13047A OA1200500291A OA1200500291A OA13047A OA 13047 A OA13047 A OA 13047A OA 1200500291 A OA1200500291 A OA 1200500291A OA 1200500291 A OA1200500291 A OA 1200500291A OA 13047 A OA13047 A OA 13047A
- Authority
- OA
- OAPI
- Prior art keywords
- compound
- alkyl
- sait
- phenyl
- chloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46490803P | 2003-04-23 | 2003-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA13047A true OA13047A (en) | 2006-11-10 |
Family
ID=33310977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200500291A OA13047A (en) | 2003-04-23 | 2004-04-13 | Cannabinoid receptor ligands and uses thereof. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20040214856A1 (xx) |
| EP (1) | EP1622903B1 (xx) |
| JP (1) | JP2006524225A (xx) |
| KR (1) | KR20060006048A (xx) |
| CN (1) | CN1809566A (xx) |
| AP (1) | AP2005003427A0 (xx) |
| AR (1) | AR044037A1 (xx) |
| AT (1) | ATE409700T1 (xx) |
| AU (1) | AU2004232552A1 (xx) |
| BR (1) | BRPI0409791A (xx) |
| CA (1) | CA2521538A1 (xx) |
| CL (1) | CL2004000827A1 (xx) |
| CO (1) | CO5640084A2 (xx) |
| DE (1) | DE602004016839D1 (xx) |
| EA (1) | EA200501504A1 (xx) |
| EC (1) | ECSP056117A (xx) |
| ES (1) | ES2309517T3 (xx) |
| GT (1) | GT200400076A (xx) |
| IS (1) | IS8054A (xx) |
| MA (1) | MA27766A1 (xx) |
| MX (1) | MXPA05011454A (xx) |
| NL (1) | NL1026027C2 (xx) |
| NO (1) | NO20055516L (xx) |
| OA (1) | OA13047A (xx) |
| PA (1) | PA8600601A1 (xx) |
| PE (1) | PE20050419A1 (xx) |
| TN (1) | TNSN05272A1 (xx) |
| TW (1) | TW200510419A (xx) |
| UY (1) | UY28276A1 (xx) |
| WO (1) | WO2004094421A1 (xx) |
| ZA (1) | ZA200508568B (xx) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4667867B2 (ja) * | 2002-08-02 | 2011-04-13 | メルク・シャープ・エンド・ドーム・コーポレイション | 置換フロ［２，３−ｂ］ピリジン誘導体 |
| EP1546115A4 (en) | 2002-09-27 | 2010-08-04 | Merck Sharp & Dohme | SUBSTITUTED PYRIMIDINES |
| US7094572B2 (en) * | 2003-03-14 | 2006-08-22 | Bristol-Myers Squibb | Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74 |
| US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| CA2524397A1 (en) * | 2003-05-07 | 2004-11-18 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
| US7232823B2 (en) * | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| US20050026983A1 (en) * | 2003-07-30 | 2005-02-03 | Pfizer Inc | Imidazole compounds and uses thereof |
| EP1682550B1 (en) * | 2003-11-04 | 2009-12-23 | Merck & Co., Inc. | Substituted naphthyridinone derivatives |
| US7151097B2 (en) * | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
| DE602005010698D1 (de) | 2004-06-09 | 2008-12-11 | Glaxo Group Ltd | Pyrrolopyridinderivate |
| US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
| CA2585925C (en) * | 2004-10-27 | 2014-04-22 | Janssen Pharmaceutica, N.V. | Tetrahydro-pyridinyl pyrazole cannabinoid modulators |
| MX2007007227A (es) * | 2004-12-17 | 2007-08-21 | Lilly Co Eli | Derivados de tiazolopiridinona como antagonistas del receptor mch. |
| CA2603104A1 (en) * | 2005-03-31 | 2006-10-12 | Janssen Pharmaceutica N.V. | Tetrahydrothiopyrano pyrazole cannabinoid modulators |
| EP1874779A1 (en) * | 2005-04-20 | 2008-01-09 | Pfizer Products Inc. | Acylaminobicyclic heteromatic compounds as cannabinoid receptor ligands |
| EP1890767A2 (en) * | 2005-05-27 | 2008-02-27 | Pfizer Products Inc. | Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
| CA2618165A1 (en) * | 2005-08-09 | 2007-02-15 | Glaxo Group Limited | Imidazopyridine derivatives as cannabinoid receptor ligands |
| US7872006B2 (en) | 2005-10-21 | 2011-01-18 | Mitsubishi Tanabe Pharma Corporation | Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity |
| AU2007222069A1 (en) * | 2006-02-21 | 2007-09-13 | Ampla Pharmaceuticals Inc. | CB1 antagonists and inverse agonists |
| JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
| WO2008039863A2 (en) * | 2006-09-27 | 2008-04-03 | Braincells, Inc. | Composition comprising a melanocortin receptor (mcr) modulating agent alone or in combination with a second neurogenic agent for treating nervous system disorders |
| PE20090142A1 (es) * | 2007-04-11 | 2009-02-19 | Merck & Co Inc | Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| CN102482312A (zh) | 2009-08-26 | 2012-05-30 | 赛诺菲 | 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途 |
| US8716482B2 (en) | 2009-09-25 | 2014-05-06 | Merck Sharp & Dohme Corp. | Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| WO2013175417A1 (en) | 2012-05-24 | 2013-11-28 | Novartis Ag | Pyrrolopyrrolidinone compounds |
| EP2948453B1 (en) | 2013-01-22 | 2017-08-02 | Novartis AG | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
| US9403827B2 (en) | 2013-01-22 | 2016-08-02 | Novartis Ag | Substituted purinone compounds |
| US9890166B2 (en) | 2013-05-27 | 2018-02-13 | Novartis Ag | Imidazopyrrolidine derivatives and their use in the treatment of disease |
| AU2014272700B2 (en) | 2013-05-28 | 2016-12-01 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease |
| EA028175B1 (ru) | 2013-05-28 | 2017-10-31 | Новартис Аг | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания |
| EA029269B1 (ru) | 2013-11-21 | 2018-02-28 | Новартис Аг | Производные пирролопирролона и их применение для лечения заболеваний |
| ES2905539T3 (es) * | 2016-03-11 | 2022-04-11 | Ac Immune Sa | Compuestos bicíclicos para diagnóstico y terapia |
| CN105878251B (zh) * | 2016-04-22 | 2019-04-09 | 上海市同济医院 | 帕金森病动物模型的制备方法及其用途 |
| WO2018222601A1 (en) | 2017-05-31 | 2018-12-06 | Chemocentryx, Inc. | 5-5 FUSED RINGS AS C5a INHIBITORS |
| US10562896B2 (en) * | 2017-05-31 | 2020-02-18 | Chemocentryx, Inc. | 6-5 fused rings as C5a inhibitors |
| MX2020006460A (es) * | 2017-12-22 | 2020-11-06 | Chemocentryx Inc | Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar. |
| CN111788185A (zh) | 2017-12-22 | 2020-10-16 | 凯莫森特里克斯股份有限公司 | 作为C5a抑制剂的二芳基取代的6,5稠合环化合物 |
| EP3773563B1 (en) | 2018-04-02 | 2024-10-16 | ChemoCentryx, Inc. | Prodrugs of fused-bicyclic c5ar antagonists |
| JP2023525081A (ja) * | 2020-05-07 | 2023-06-14 | エーシー・イミューン・エス・アー | 診断のための新規化合物 |
| CN117460731A (zh) * | 2021-06-11 | 2024-01-26 | 劲方医药科技(上海)有限公司 | 杂环内酰胺类化合物，其制法与医药上的用途 |
| MX2024001868A (es) * | 2021-08-11 | 2024-05-29 | Landos Biopharma Inc | Ligandos analogos de tetrahidropirazolopiridina de nlrx1 y usos de los mismos. |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3340269A (en) * | 1964-09-08 | 1967-09-05 | Ciba Geigy Corp | 1-substituted 4-acyl-2, 3-dioxo-piperidine |
| US3365459A (en) * | 1964-09-08 | 1968-01-23 | Ciba Geigy Corp | Certain tetrahydro pyrazolo-pyridine and pyrazolo-piperidine derivatives |
| GB8613591D0 (en) * | 1986-06-04 | 1986-07-09 | Roussel Lab Ltd | Chemical compounds |
| ES2037739T3 (es) * | 1986-10-22 | 1993-07-01 | Ciba-Geigy Ag | Derivados del acido 1,5-difenilpirazol-3-carboxilico para la proteccion de plantas de cultivo. |
| PH27357A (en) * | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
| FR2665898B1 (fr) * | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2714057B1 (fr) * | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
| US5596106A (en) * | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
| FR2741621B1 (fr) * | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| US6100259A (en) * | 1997-01-21 | 2000-08-08 | Smithkline Beecham Corporation | Cannabinoid receptor modulators |
| FR2758723B1 (fr) * | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| FR2761266B1 (fr) * | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
| IL141769A0 (en) * | 1998-09-11 | 2002-03-10 | Aventis Pharma Sa | Azetidine derivatives, preparation and medicines containing them |
| FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
| AU2001234958A1 (en) * | 2000-02-11 | 2001-08-20 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| US6479479B2 (en) * | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
| US6566356B2 (en) * | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
| US6355631B1 (en) * | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
| MXPA02009258A (es) * | 2000-03-23 | 2005-04-19 | Solvay Pharm Bv | Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonistica de cannabis-1. |
| US20020019421A1 (en) * | 2000-07-05 | 2002-02-14 | Roni Biberman | Compositions and therapy for substance addiction |
| US20020091114A1 (en) * | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
| WO2003007887A2 (en) * | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| US6509367B1 (en) * | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
| US20030139386A1 (en) * | 2001-12-21 | 2003-07-24 | Sophie Cote | Pharmaceutical compositions based on azetidine derivatives |
| US6825209B2 (en) * | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
| AU2003267728A1 (en) * | 2002-10-18 | 2004-05-04 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
| US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US7247628B2 (en) * | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| US7268133B2 (en) * | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
-
2004
- 2004-04-12 US US10/823,152 patent/US20040214856A1/en not_active Abandoned
- 2004-04-13 AT AT04727076T patent/ATE409700T1/de not_active IP Right Cessation
- 2004-04-13 AU AU2004232552A patent/AU2004232552A1/en not_active Abandoned
- 2004-04-13 WO PCT/IB2004/001357 patent/WO2004094421A1/en active IP Right Grant
- 2004-04-13 CN CNA2004800175674A patent/CN1809566A/zh active Pending
- 2004-04-13 MX MXPA05011454A patent/MXPA05011454A/es unknown
- 2004-04-13 JP JP2006506562A patent/JP2006524225A/ja not_active Abandoned
- 2004-04-13 ES ES04727076T patent/ES2309517T3/es not_active Expired - Lifetime
- 2004-04-13 DE DE602004016839T patent/DE602004016839D1/de not_active Expired - Fee Related
- 2004-04-13 CA CA002521538A patent/CA2521538A1/en not_active Abandoned
- 2004-04-13 OA OA1200500291A patent/OA13047A/en unknown
- 2004-04-13 KR KR1020057020010A patent/KR20060006048A/ko not_active Application Discontinuation
- 2004-04-13 AP AP2005003427A patent/AP2005003427A0/xx unknown
- 2004-04-13 BR BRPI0409791-2A patent/BRPI0409791A/pt not_active IP Right Cessation
- 2004-04-13 EP EP04727076A patent/EP1622903B1/en not_active Expired - Lifetime
- 2004-04-13 EA EA200501504A patent/EA200501504A1/ru unknown
- 2004-04-16 CL CL200400827A patent/CL2004000827A1/es unknown
- 2004-04-20 GT GT200400076A patent/GT200400076A/es unknown
- 2004-04-20 PA PA20048600601A patent/PA8600601A1/es unknown
- 2004-04-20 PE PE2004000389A patent/PE20050419A1/es not_active Application Discontinuation
- 2004-04-21 AR ARP040101339A patent/AR044037A1/es unknown
- 2004-04-21 UY UY28276A patent/UY28276A1/es not_active Application Discontinuation
- 2004-04-22 TW TW093111297A patent/TW200510419A/zh unknown
- 2004-04-23 NL NL1026027A patent/NL1026027C2/nl not_active IP Right Cessation
-
2005
- 2005-09-29 IS IS8054A patent/IS8054A/is unknown
- 2005-10-21 TN TNP2005000272A patent/TNSN05272A1/fr unknown
- 2005-10-21 EC EC2005006117A patent/ECSP056117A/es unknown
- 2005-10-21 CO CO05106974A patent/CO5640084A2/es not_active Application Discontinuation
- 2005-10-21 ZA ZA200508568A patent/ZA200508568B/en unknown
- 2005-10-21 MA MA28565A patent/MA27766A1/fr unknown
- 2005-11-22 NO NO20055516A patent/NO20055516L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR044037A1 (es) | 2005-08-24 |
| ECSP056117A (es) | 2006-03-01 |
| ES2309517T3 (es) | 2008-12-16 |
| PA8600601A1 (es) | 2005-05-24 |
| KR20060006048A (ko) | 2006-01-18 |
| CO5640084A2 (es) | 2006-05-31 |
| WO2004094421A1 (en) | 2004-11-04 |
| TNSN05272A1 (fr) | 2007-07-10 |
| AP2005003427A0 (en) | 2005-12-31 |
| TW200510419A (en) | 2005-03-16 |
| ZA200508568B (en) | 2007-04-25 |
| DE602004016839D1 (de) | 2008-11-13 |
| MXPA05011454A (es) | 2005-12-12 |
| NO20055516L (no) | 2005-11-22 |
| IS8054A (is) | 2005-09-29 |
| GT200400076A (es) | 2004-12-16 |
| EP1622903A1 (en) | 2006-02-08 |
| MA27766A1 (fr) | 2006-02-01 |
| AU2004232552A1 (en) | 2004-11-04 |
| CA2521538A1 (en) | 2004-11-04 |
| UY28276A1 (es) | 2004-11-30 |
| NL1026027A1 (nl) | 2004-10-27 |
| JP2006524225A (ja) | 2006-10-26 |
| EP1622903B1 (en) | 2008-10-01 |
| NL1026027C2 (nl) | 2005-07-05 |
| EA200501504A1 (ru) | 2006-04-28 |
| BRPI0409791A (pt) | 2006-05-30 |
| PE20050419A1 (es) | 2005-06-18 |
| ATE409700T1 (de) | 2008-10-15 |
| CN1809566A (zh) | 2006-07-26 |
| CL2004000827A1 (es) | 2005-03-04 |
| US20040214856A1 (en) | 2004-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1622903B1 (en) | Cannabinoid receptor ligands and uses thereof | |
| US7232823B2 (en) | Cannabinoid receptor ligands and uses thereof | |
| US7354929B2 (en) | Cannabinoid receptor ligands and uses thereof | |
| US7145012B2 (en) | Cannabinoid receptor ligands and uses thereof | |
| US7247628B2 (en) | Cannabinoid receptor ligands and uses thereof | |
| US20040157838A1 (en) | Cannabinoid receptor ligands and uses thereof | |
| WO2004099157A1 (en) | Cannabinoid receptor ligands and uses thereof | |
| EP1638570A1 (en) | Pyrimidine derivatives as cannabinoid receptor ligands | |
| WO2006111849A1 (en) | Acylaminobicyclic heteromatic compounds as cannabinoid receptor ligands | |
| WO2005103052A1 (en) | Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof | |
| US20050026983A1 (en) | Imidazole compounds and uses thereof | |
| WO2005061507A1 (en) | Bicyclic pyrazol-4-one cannabinoid receptor ligands and uses thereof | |
| WO2005061505A1 (en) | Bicyclic imidazolyl pyrimidin-4-one cannabinoid receptor ligands and uses thereof | |
| WO2005061506A1 (en) | Bicyclic pyrazolyl and imidazolyl compounds as cannabinoid receptor ligands and uses thereof | |
| WO2005061504A1 (en) | Bicyclic pyridazinone cannabinoid receptor ligands and uses thereof | |
| US20070213334A1 (en) | Cannabinoid receptor ligands and uses thereof |